| 货号 | 规格 | 价格 | 上海 | 北京 | 珠海 | 重庆 | 武汉 | 购买数量 |
|---|---|---|---|---|---|---|---|---|
S89561-1mg促销 |
99.56% | ￥792.00 ￥560.00 |
4 | 2 | 2 | - | - |
|
S89561-5mg买3赠1 |
99.56% | ￥1750.00 ￥1400.00 |
4 | - | - | - | - |
|
S89561-10mg买3赠1 |
99.56% | ￥2410.00 ￥1920.00 |
5 | - | - | - | - |
|
S89561-25mg促销 |
99.56% | ￥5290.00 ￥4230.00 |
5 | - | - | - | - |
|
S89561-50mg促销 |
99.56% | ￥7600.00 ￥6080.00 |
2 | - | - | - | - |
|
S89561-100mg促销 |
99.56% | ￥13300.00 ￥10640.00 |
2 | - | - | - | - |
|
| 产品描述： | Dxd (Exatecan derivative for ADC) is a potent DNA topoisomerase I inhibitor, with an IC50 of 0.31 μM, used as a conjugated drug of HER2-targeting ADC (DS-8201a). | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 靶点： | Topoisomerase I:0.31 μM (IC50);Camptothecins;Topoisomerase | ||||||||||||||||||||
| 体外研究： | Dxd shows obviously suppression on the HER2-positive KPL-4, NCI-N87, and SK-BR-3 cell lines with IC50s of 26.8, 25.4, and 6.7 ng/mL respectively, but with no such inhibition on MDA-MB-468 (IC50, >10,000 ng/mL) | ||||||||||||||||||||
| 体内研究： | Dxd is cytotoxic to human cancer cell lines of KPL-4, NCI-N87, SK-BR-3, and MDA-MB-468 with IC50s of 1.43 nM-4.07 nM. In HER2 low-expressing ST565 and ST313 models has HER2 IHC 1+/FISH-negative expression | ||||||||||||||||||||
| 参考文献： | 1. Ogitani Y, et al. DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1. Clin Cancer Res. 2016 Oct 15;22(20):5097-5108. | ||||||||||||||||||||
| 溶解性： | Soluble in DMSO | ||||||||||||||||||||
| 保存条件： | -20℃ | ||||||||||||||||||||
| 配置溶液浓度参考： |
|
||||||||||||||||||||
| 注意： | 部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
沪公网安备 31011702002021号
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
